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1. Introduction  
There is increasing evidence to suggest that viruses have aetiological roles in inflammatory 
myopathies. It has been reported that viruses, by means of direct infection of the skeletal 
muscle, can cause myalgias, polymyositis, and virus-associated rhabdomyolysis. It has also 
been found that some viruses can cause myositis through a secondary immune-mediated 
phenomenon. In addition, there are emerging reports of cases of idiopathic polymyositis 
suspected to be associated with infectious agents, predominantly viruses.  
Arthrogenic alphaviruses such as chikungunya virus (CHIKV), Ross River virus (RRV) and 
sindbis virus (SINV) are known to cause outbreaks of polyarthritis worldwide (Griffin, 
2007). The clinical presentation of alphavirus infection includes fever, rash, arthralgia, and 
arthritis, however, one of the predominant features of alphaviral disease is myalgia with 
corresponding myositis. The recent outbreaks of CHIKV in several countries surrounding 
the Indian Ocean have seen millions of people affected, with case reports showing a high 
incidence of myalgia and skeletal muscle involvement.  
The ability of these viruses to cause long-term disease sequelae persisting for months or 
even years after the initial infection is of particular interest. Although difficult to 
substantiate indefinitely, there is significant reason to suspect that this long-term impact, 
combined with the virus‘s ability to cause acute muscle damage, could make arthrogenic 
viruses a potential cause of idiopathic inflammatory myopathies.  
The mechanisms by which alphaviruses cause musculoskeletal disease are now being 
unraveled with clear evidence to suggest that the viral-induced inflammatory response can 
lead to destruction of striated muscle fibres, providing a possible cause for the symptoms of 
myalgia. In recent years, the use of animal models of alphavirus-induced myositis has 
increased our understanding of the inflammatory myopathies caused by these viruses. 
Using these animal models it has been shown that in the acute phase of infection, skeletal 
muscle is the major site of viral replication, resulting in striated muscle fibre destruction 
(Lidbury et al., 2000; Morrison et al., 2006). In the sub-acute phase of infection, the virus 
triggers an extensive inflammatory immune response, resulting in the influx of 
inflammatory cells and production of soluble mediators, leading to extensive myositis. The 
use of animal models has been instrumental in elucidating the role of alphaviruses as 
triggers of inflammatory myopathies.  
This chapter will discuss the role of alphavirus infections as triggers of myositis, including 
how animal models are being used to dissect the pathobiology of disease and identify 
potential drug candidates to ameliorate disease. 
www.intechopen.com
 Idiopathic Inflammatory Myopathies – Recent Developments 44
2. Alphaviruses  
Alphaviruses are a group of mosquito-transmitted viruses of the Togaviridae family. The 
virus particle is approximately 60 nm in size and is comprised of a single–strand of 
ribonucleic acid (RNA) of approximately twelve kilobases, encased in a nucleocapsid with a 
lipid membrane envelope.  The RNA genome is divided into two regions, the non-structural 
and the structural regions. The non-structural region encodes four nonstructural proteins  
(nsPs; nsP1 to nsP4), and the structural region encodes the capsid protein (C) and three 
glycoproteins (E1, E2 and E3). The glycoproteins E1 and E2 protrude from the viral lipid 
envelope and are the most external and immunodominant epitopes being exposed to a 
significant amount of immune pressure.  
The Alphavirus genus can be classified into two subgroups depending on differences in 
disease aetiologies; the Old World and the New World alphaviruses. The Old World 
alphaviruses, including RRV, o'nyong-nyong (ONNV), Semliki Forest virus (SFV), SINV, 
mayaro virus (MAYV), Barmah Forest virus (BFV) and CHIKV, typically cause fever, rash, 
myalgia, arthralgia and arthritis in humans, with symptoms often persisting for several 
months to years following infection (Table 1) (Suhrbier & La Linn, 2004). The New World 
alphaviruses, including Venezuelan equine encephalitis virus (VEEV), Eastern equine 
encephalitis virus (EEEV) and Western equine encephalitis virus (WEEV), cause severe 
disease in humans targeting the central nervous system (CNS), often resulting in 
encephalitis (Johnston & Peters, 1996), and are not associated with myositis. This chapter 
will focus on Old World alphaviruses. 
Old World alphaviruses have been associated with large outbreaks of disease worldwide. 
These outbreaks are often explosive in nature, affecting many thousands to millions of 
people such as the 1959-1962 outbreak of ONNV fever in Africa, involving an estimated two 
million cases (Lanciotti et al., 1998; Posey et al., 2005; Williams et al., 1965), the 1979-1980 
outbreak of RRV in the South Pacific, resulting in more than 60,000 reported cases (Harley et 
al., 2001) and the 2005-2006 outbreak of CHIKV in India with at least 1.5 million people 
affected (Josseran et al., 2006; Kalantri et al., 2006; Yergolkar et al., 2006). In addition to the 
larger outbreaks, alphaviruses are also known to cause smaller, sporadic outbreaks such as 
that of MAYV in Brazil in 1978 and 2008 (Azevedo et al., 2009; Pinheiro et al., 1981), 
outbreaks of SINV in Finland and Sweden as the causative agent of Pogosta and Ockelbo 
diseases respectively (Kurkela et al., 2004; Skogh & Espmark, 1982) and the recent 2009 
outbreaks of CHIKV in Thailand, Singapore, Malaysia and Indonesia (Hapuarachchi et al., 
2010; Higgs & Ziegler, 2010; Ng et al., 2009a; Thavara et al., 2009; Theamboonlers et al., 2009). 
Although the predominant clinical feature in most alphaviral outbreaks is the typical 
arthritis/arthralgia, a second important feature of the disease is myalgia.  
The course of a typical alphavirus infection first involves the bite of an infected mosquito, 
resulting in subcutaneous inoculation of the virus. This is then followed by the initial viral 
replication and systemic viraemic spread. The primary viraemia marks the acute phase of 
the infection. Infection progresses to secondary sites where the virus can replicate, however, 
by this stage the body mounts an immune response to counteract the virus. It is at this point 
that specific clinical signs and symptoms of disease commence, which correlate closely to 
the immune inflammatory response, and mark the sub-acute phase of infection. The sub-
acute phase can last several weeks, and there have been numerous cases documented where 
disease symptoms have lasted for months to years, thereby marking the chronic stage of 
alphaviral infection. In all three stages of alphaviral infection; acute, sub-acute and chronic, 
there is clear evidence of inflammatory response in the muscle and symptoms of myalgia.  
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Table 1. Old World viruses of the Alphavirus genus. 
2.1 Ross River virus (RRV)  
RRV was first isolated in 1959 in Queensland, Australia and was identified as an arbovirus 
causing polyarthritis by the early 1960s. It circulates endemically in Australia and the South 
Pacific (Harley et al., 2001). Like all alphaviruses, the virus is maintained in transmission 
cycles between its mosquito vector and vertebrate hosts. In the case of RRV the predominant 
vectors are the mosquitoes Culex annulirostris and Aedes vigilax and the vertebrate hosts are 
commonly found to be native marsupials (Harley et al., 2001; Old & Deane, 2005; Oliveira et 
al., 2006). In Australia, there are between 5,000 to 8,000 cases of RRV reported annually 
(Harley et al., 2001), with patients displaying symptoms of arthritis, arthralgia, myalgia, 
fatigue, febrile illness and rash (Fraser, 1986; Harley et al., 2002; Harley et al., 2001).  
The characteristic feature of RRV-infection in its acute stage is a febrile illness, which is 
frequently ignored by patients. Following the non-specific fever, comes the onset of RRV-
specific symptoms, such as rash, arthritis, arthralgia and myalgia. It is at this sub-acute stage 
that patients generally seek medical attention, with infection confirmed by the detection of 
virus-specific IgM/IgG in the serum. The acute symptoms can last for weeks to months, 
however chronic disease associated with RRV infection in some cases has been reported to 
last up to a year or more (Mylonas et al., 2002).  
A survey conducted in southeast Queensland of 67 adult patients with RRV disease found 
that RRV disease was often severe at onset, with patients presenting predominantly with 
polyarthralgia. Around one third to one half also experienced rash, fever, myalgia, and/or 
fatigue. In all but 2% of cases, symptoms resolved over an average 3 to 6-month period.  In 
the 2% of cases, symptoms appeared to last longer than 1 year (Mylonas et al., 2002). These 
clinical features are common in RRV-infected patients.  
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2.1.1 Models of RRV disease 
A small animal model of RRV-disease has been developed in 20-24 day old C57BL/6 mice 
(Lidbury et al., 2008; Morrison et al., 2007; Morrison et al., 2006), subcutaneously infected 
with RRV. The infection progresses with virus titre peaking in the first 24-48 hours post-
infection (p.i.), with virus detected in the serum, skeletal muscles and joints, indicative of 
productive infection. Disease onset is observed by 4-5 days p.i., with clinical disease signs 
that include ruffled fur and weight loss. By 7-12 days p.i., peak disease is reached, with 
severe hind limb dysfunction observed to the point of paralysis, loss of grip strength and 
severe weight loss; at this point viraemia is no longer detectable. The infection elicits an 
inflammatory response, detectable primarily within the muscle tissues, with severe myositis 
observed in the skeletal muscle (Figure 1). By 15-21 days p.i., the disease signs resolve, with 
mice regaining hind limb function and beginning to gain weight. By 30 days p.i. mice show 
no signs of disease, although myositis is still evident (Figure 1F). Interestingly, histology of 
the myofibres shows the presence of centralized nuclei indicative of muscle fibre 
regeneration (Morrison et al., 2006).  
2.2 Chikungunya virus (CHIKV) 
CHIKV was first isolated during an outbreak of dengue-like fever in Tanzania in 1952 
(Robinson, 1955). Due to the similarities in febrile illness, it is possible that CHIKV may have 
been assumed as dengue fever for hundreds of years (Carey, 1971). The word ‘chikungunya’ 
comes from the Makonde language of Tanzania, and means ‘that which bends up’, which 
describes the clinical signs of disease frequently observed in CHIKV-infected patients 
(Griffin, 2007).  The current geographical distribution of CHIKV covers the continents of 
Africa and Asia including India and the islands of the Indian Ocean. The original vector of 
CHIKV is Aedes aegypti with transmission cycles existing between vector and monkeys, 
however Aedes albopictus has been implicated as the vector responsible for a number of the 
recent outbreaks and the resulting spread of CHIKV into new global regions.  
Since its identification in 1952 (Ross, 1956), laboratory-confirmed outbreaks of CHIKV have 
occurred annually in south and central Africa and South East Asia (Higgs & Ziegler, 2010). 
Recently, the re-emergence of CHIKV in the French island of La Réunion saw a third of the 
population infected (more than 250,000 people) (Renault et al., 2007). The virus then rapidly 
spread to the Indian Ocean, India and South East Asia, with estimates as high as five million 
reported cases since 2006 (Josseran et al., 2006; Kalantri et al., 2006; Yergolkar et al., 2006). 
CHIKV cases have also been reported among travellers in Europe and the USA (Liumbruno 
et al., 2008) with a localised outbreak occurring in Italy (Enserink, 2007). Currently the virus 
continues to circulate and cause sporadic outbreaks in the Asia Pacific region, the most 
recent being the 2009 outbreaks in South East Asia affecting more than 100,000 people 
(Centers-for-Disease-Control-and-Prevention, 15 August 2010; Thavara et al., 2009; 
Theamboonlers et al., 2009).  
Typical symptoms of CHIKV infection are abrupt febrile illness, headache, arthralgia, 
myalgia and in some cases maculopapular rash. Similar to other alphaviruses the incubation 
period for CHIKV ranges from 3 to 7 days, and as few as 5% of the CHIKV cases are 
asymptomatic. The acute signs and symptoms usually resolve in less than 2 weeks, but 
arthralgia and myalgia may linger for weeks, months or even years (Couderc & Lecuit, 2009; 
Jaffar-Bandjee et al., 2009). This acute phase of infection is frequently more severe in both 
newborns and elderly patients who often have an extremely high viral load (Jaffar-Bandjee 
et al., 2009). As with other alphaviruses the sub-acute phase, defined by the presence of 
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arthralgia and myalgia, appears to be largely modulated by the immune system’s response 
to the invading pathogen. The chronic phase of CHIKV infection has been studied more 
extensively than that of other alphaviruses and appears to be associated with the persistence 
of specific IgM and chronic arthralgia/myalgia (Jaffar-Bandjee et al., 2009). It is postulated 
that the ongoing symptoms may be linked to the virus’s capacity to persist in tissues by 
mechanisms that currently remain ill-characterised. 
 
 
Fig. 1. RRV induces inflammation in hind limb skeletal muscle tissue of C57BL/6 mice. Mice 
were infected with RRV or mock-infected with diluent (PBS). At 3, 5, 7, 10, and 30 days post-
infection (p.i.), mice were sacrificed, quadriceps removed, 5 µm sections generated then 
H&E stained. (A) Mock infection, (B) RRV 3 days p.i., (C) RRV 5 days p.i., (D) RRV 7 days 
p.i., (E) RRV 10 days p.i. and (F) RRV 30 days p.i. (magnification, x200). Copyright © 2006, 
American Society for Microbiology. All Rights Reserved. Journal of Virology, Jan. 2006, 
p.737–749 Vol. 80, No. 2 0022-538X/06/$08.00_0doi:10.1128/JVI.80.2. 737– 749.2006. 
2.2.1 Models of CHIKV disease 
Currently three different mouse models of CHIKV infection have been developed. Neonatal 
C57BL/6 inbred mice and CD-1 outbred mice were found to be susceptible to CHIKV 
infection, showing an age-dependent disease severity with a model established in 14-day-
old mice (Couderc et al., 2008; Morrison et al., 2011; Ziegler et al., 2008). These models show 
extensive myositis in the skeletal muscle at 7-10 days p.i. during the stage of sub-acute 
infection (Morrison et al., 2011). Subcutaneous infection of adult C57BL/6 mice leads to a 
self-limiting disease characterised by arthritis, tenosynovitis and myositis. Histological 
studies revealed a pronounced infiltration of monocytes, macrophages and natural killer 
(NK) cells in muscle tissues and synovial membranes indicative of myositis and arthritis 
(Gardner et al., 2010). Finally, adult mice partially deficient in the type I interferon (IFN) 
receptor (IFN-/R+/-) developed mild CHIKV infection which closely resembles the 
course of human infection, with virus recovered from muscles, joints and skin (Couderc et 
al., 2008).  
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In addition to the use of small animal models, some studies have utilized non-human 
primates to investigate the mechanisms of CHIKV disease. A model was developed in 
cynomolgus macaques (Macaca fascicularis) to closely mimic the human disease and to test 
the effectiveness of immunological interventions (Labadie et al., 2010). In this model, 
viraemia peaked at two days p.i. and subsided by 15 days p.i., with extensive mononuclear 
cell infiltration in the lymphoid tissues and liver of infected macaques. Long-term infection 
was also observed, with the virus persisting in the lymphoid organs, liver, joints and 
muscles. However, the major limitation with this study was the lack of pathology observed 
in muscle and joint tissues, which is not consistent with observations in humans.  
2.3 Sindbis virus (SINV)  
SINV is found world-wide and is the most widely distributed of all known arboviruses 
(Tesh, 1982). It was first identified in 1952, being isolated from Culex mosquitoes collected in 
the village of Sindbis near Cairo (Taylor et al., 1955). The first description of clinical 
symptoms of SINV infection came from a single case in Uganda in 1961 and included fever, 
malaise, pains in the joints, muscles and tendons, and rash (Malherbe et al., 1963). 
In Europe, SINV is the causative agent of Ockelbo, Pogosta, and Karelian fever, all of which 
exhibit significant morbidity. These fevers are named according to the regions where they 
circulate, despite being similar in clinical presentations. The major symptoms in addition to 
joint and muscle inflammation are fever, fatigue, headache and rash (Laine et al., 2004). The 
diagnosis is based on the clinical picture and serology. The musculoskeletal symptoms of 
SINV infection may also continue long-term with chronic SINV-associated disease 
symptoms being identified in a number of cases 2.5 years after the onset (Laine et al., 2000).   
SINV outbreaks occur in Europe in common cycles. In 1981 Sweden reported 54 cases 
(Ockelbo), Russia 200 cases (Karelian) and Finland 300 cases (Pogosta) of clinically and 
serologically diagnosed SINV infection (Brummer-Korvenkontio et al., 2002; Espmark & 
Niklasson, 1984; L'Vov D et al., 1982). Outbreaks of Pogosta disease have thus far emerged 
every seven years since the first outbreak was noted in 1974, including a large outbreak in 
2002 (Sane et al., 2010).  
2.3.1 Models of SINV disease 
Several mouse models of SINV infection have been developed; one of particular relevance 
involves the subcutaneous injection of neonatal outbred mice with SINV. In this model, 
primary replication of the virus occurs in the skin, fibroblasts and connective tissues, 
followed by systemic viraemia (Johnson, 1965). The SINV-induced inflammatory response is 
characterised by extensive virus replication in extraneural tissues and induction of high 
levels of pro-inflammatory cytokines and corticosterone, with mice frequently dying of 
inflammatory disease by day 5 p.i. (Klimstra et al., 1999; Trgovcich et al., 1996; Trgovcich et 
al., 1997). Although these studies show the onset of myositis in skeletal muscle, the major 
limitation of this model is the rapid mortality.   
2.4 Other alphaviruses 
Barmah Forest virus (BFV) is a closely related alphavirus and shares a similar distribution to 
RRV. BFV infection is believed to be largely under-diagnosed due to the similarity to RRV in 
disease presentation and geographic distribution (McGill, 1995). However, the clinical 
disease presentation of BFV infection has been documented to involve arthralgia and 
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myalgia, suggesting that this is another alphavirus with the potential for causing an 
inflammatory myopathy (Jacups et al., 2008).  
O’nyong-nyong virus (ONNV) is an alphavirus antigenically related to CHIKV. It was first 
isolated in East Africa and continues to circulate endemically in Africa producing a similar 
disease presentation to CHIKV-infection. Between 1959 and 1962 there was a large outbreak 
of ONNV in East Africa involving an estimated 2 million people in which 71% of infected 
patients suffered from myalgia (Posey et al., 2005; Williams et al., 1965).  In 1996-1997 ONNV 
re-emerged in south-central Uganda (Kiwanuka et al., 1999) and is another alphavirus with 
the potential to cause global outbreaks of disease.  
Mayaro virus (MAYV) was first isolated in 1954 and is endemic to South America where it 
causes sporadic cases and smaller outbreaks of disease that manifest with fever, headaches, 
athralgia and myalgia (Anderson et al., 1957). Cases of MAYV infection and outbreaks have 
been documented in Trinidad, Surinam, Brazil, Bolivia, French Guinea and Peru (Tesh et al., 
1999). Moreover, imported cases of MAYV infection have been recently reported in two 
European countries demonstrating a potential for this virus to spread to non-endemic areas 
(Hassing et al., 2010; Receveur et al., 2010). A study of cases of MAYV in Peru by Tesh et al.  
found myalgia to be a predominant symptom with a prevalence of 77.3%. The strong level 
of muscle involvement in MAYV infection, coupled with the incidences of MAYV spread 
into other regions makes this an important virus causing myosits. 
Semliki Forest virus (SFV) was first isolated in 1942 in Uganda from Aedes abnormalis 
mosquitoes in the Semliki Forest. Despite SFV being the most extensively studied member 
of the alphavirus genus, the virus has rarely been documented as causing disease in 
humans. The few reported cases of human disease have involved headache, arthralgia and 
myalgia, presentations that are commonly associated with other alphavirus disease 
manifestation. In 1987 an outbreak of SFV was recorded in the Central African Republic 
with severe and prolonged myalgia as a major clinical symptom (Mathiot et al., 1990).   
3. Tissue tropism and myositis in acute alphavirus infection  
During the acute phase of a viral infection the cells and tissues that are infected can affect 
both the progression and clinical attributes of the disease. In CHIKV infection, skeletal 
muscle is the primary site of virus infection and replication, resulting in muscle fibre 
destruction and subsequent myositis. One of the difficulties in studying infection with 
CHIKV and other alphaviruses is that the incubation period and acute phase of infection, at 
the onset of primary viraemia, often produces non-specific symptoms that patients do not 
report and therefore clinicians are rarely able to document the early stages of infection. 
Furthermore, since alphaviruses produce non-fatal diseases, histopathological studies in 
humans are generally uncommon. 
There have been numerous studies on alphaviral tropism in vitro, but these studies can only 
provide limited information on the mechanisms of the acute phase of infection, as they may 
not fully relate to the natural course of virus infection in vivo. The establishment of animal 
models of disease, in mice and macaques, has helped in progressing the understanding of 
alphavirus pathogenesis. In particular, cells derived from muscle tissues have been 
identified as sites of infection. Infected muscle cells undergo cell death, leading to muscle 
tissue damage and myositis, which commences at the sub-acute phase of infection. 
www.intechopen.com
 Idiopathic Inflammatory Myopathies – Recent Developments 50
3.1 Models of acute alphavirus infection in vivo  
In animal models of RRV and CHIKV infection, virus initially replicates at the site of 
inoculation before being disseminated through the blood stream to other tissues such as 
skeletal muscle and joint tissues (Gardner et al., 2010; Labadie et al., 2010; Morrison et al., 
2011; Morrison et al., 2006). Replication in skeletal muscle results in severe necrotic myositis 
with extensive myofibre destruction (Couderc & Lecuit, 2009). The damage to the skeletal 
muscle was clearly demonstrated using Evan’s Blue dye (EBD) staining of affected tissues. 
EBD is commonly used to identify disrupted tissues as the tissues become permeable to EBD 
uptake. Following viral infection and replication, muscle tissues exhibit extensive tissue 
destruction, shown by prominent EBD staining (Figure 2). The occurrence of tissue 
pathology following viral infection and replication may correspond to the onset of myositis. 
 
 
Fig. 2. RRV-infection causes skeletal tissue damage in mice. C57BL/6 mice were mock-
infected (A) or infected with RRV (B). At 10 days p.i. mice were injected with 1% Evans Blue 
dye (EBD) and six hours later mice were sacrificed, quadriceps muscle removed and 10 m 
cryosections generated. The uptake of EBD (red) and DAPI (blue; for nuclei staining) was 
visualised by fluorescence microscopy (magnification, x200). 
Within the skeletal muscle, the cells targeted by the virus have been identified as fibroblasts 
and muscle satellite cells. In CHIKV-infected IFN-/ receptor deficient mice, fibroblasts 
within the skeletal muscles and joint connective tissues were found to be the main target for 
infection (Couderc et al., 2008). Analysis of CHIKV-infected human muscle, joint and skin 
biopsy samples confirmed these observations, with fibroblasts and muscle satellite cells 
identified as major targets in peripheral tissues (Couderc & Lecuit, 2009; Ozden et al., 2007). 
3.2 Cells susceptible to alphavirus infection in vitro  
There are a number of in vitro studies demonstrating the permissibility of various cells to 
alphavirus infection. Although these studies have limitations, they provide insight into the 
cell types that may be the target of infection in vivo. CHIKV and RRV are known to infect 
cells of epithelial and fibrobast origin and some immune cells (Sourisseau et al., 2007).  
Myogenic progenitor cells have been shown to be permissive to CHIKV infection (Ozden et 
al., 2007). A study by Sourisseau et al., characterised permissibility to CHIKV infection in a 
number of human cell types. The study demonstrated that several cells that can be found 
within muscle tissues such as primary fibroblasts, endothelial cells and immune cells such 
as monocyte-derived macrophages were susceptible to CHIKV infection (Sourisseau et al., 
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2007). Virus infection and replication in these cells in vitro results in rapid shut down of host 
cell transcription and translation resulting in cytopathic effect (CPE) and cell death. Studies 
of CHIKV in epithelial (HeLa) cells in vitro have shown infection can lead to apoptosis 
which may help explain the destruction of muscle fibres seen in vivo (Sourisseau et al., 2007). 
4. Sub-acute alphavirus infection and myositis  
Severe forms of alphavirus disease result in chronic incapacitating myalgia, arthralgia and 
arthritis. One of the major reasons for the lack of information on the mechanisms of how 
these viruses cause musculoskeletal disease is due to the absence of studies in humans. 
Patients often only report on the symptoms they feel, and in most cases the acute phase of 
infection often go unreported, and the full extent of the disease not properly documented. 
One of the key questions is whether the symptoms of arthralgia and myalgia are a result of 
myositis and if so, how is the inflammatory process triggered. In recent years, the use of 
animal models of alphaviral-induced disease has assisted in unraveling the pathobiology of 
infection. By combining the clinical findings from human cases with findings from animal 
models, a clearer understanding of how alphaviruses cause myalgia and myositis is 
emerging (see Figure 3 for an overview).  
4.1 Clinical observations for sub-acute alphavirus induced myopathies  
There have been several studies on the clinical presentation of RRV disease, however most 
of these studies have focused largely on clinical reports based on patient feedback and 
limited biochemical and immunological analyses of patient’s blood.  There have been a 
limited number of studies on human synovial tissues. These studies have focused on the 
synovial fluid to determine the nature of the cellular infiltrates (Fraser, 1986; Fraser et al., 
1981). Unfortunately, these studies did not extend to muscle tissues. Similarly, studies on 
human SINV infection with Pogosta disease mainly involved analysis of human serum for 
antibody and viral antigen detection.  
Human CHIKV infection has been clinically well documented (Chow et al., 2011; Pialoux et 
al., 2007; Powers & Logue, 2007; Simon et al., 2007; Sissoko et al., 2010; Taubitz et al., 2007). 
The serology profile during the course of infection has been documented by numerous 
studies, showing that viraemia lasts 5-7 days (acute infection), with a subsequent 
IgM+/IgG- sub-acute infection progressing for a further week until IgG antibodies are 
detected and in some cases IgM was still detectable (Staikowsky et al., 2009). Interestingly, it 
has been reported that levels of IgM have remained high for months and even years in many 
cases of alphavirus infection (Chopra et al., 2008; Kurkela et al., 2005; Niklasson et al., 1988). 
In addition, it has been suggested that the presence of IgM may serve as a marker for viral 
persistence, whereby latent infection may be linked to the long term disease sequelae and 
chronic pathologies associated with alphavirus infection, including the on-going 
inflammatory myopathies (Jaffar-Bandjee et al., 2009) 
A study by Ozden et al., analysed muscle biopsies of CHIKV-infected patients providing 
new insight into CHIKV pathogenesis in muscle tissues (Ozden et al., 2007). Patients were 
either IgM+ or IgG+ without detectable viraemia and were therefore classified as being in 
the sub-acute or recurring stage of infection. In a CHIKV patient presenting with recurrent 
symptoms including fever, arthralgia and myalgia, histological analysis of muscle biopsies 
demonstrated atrophy and necrosis (Figure 4A and 4D) and vacuolization of muscle fibres 
(Figure 4B) and interstitial mixed acute and chronic inflammation (Figure 4C). Viral antigens 
were detected in the periphery of muscle fibres in single cells (Figure 5B, 5C) or in groups of 
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cells (Figure 5A, 5D). Viral antigen was also detected (to lower levels) in the muscle biopsy 
of a patient with recurrent infection (Figure 5F), indicating that muscle satellite cells may 
harbour persistent alphaviral infection.  
 
 
*Modeled on CHIKV infection (Labadie et al., 2010) 
Fig. 3. Comparison of symptoms resulting from naturally human alphavirus infection, 
laboratory-infected nonhuman primate model of CHIKV, and laboratory-infected 
alphavirus mouse-models. Infection is broken down into three stages: acute, sub-acute, and 
chronic. The acute phase is defined by the presence of viraemia, the sub-acute phase is 
defined by the presence of IgM+ antibodies and the chronic phase is defined by IgG+ 
conversion. The chronic phase in humans includes persistent and recurrent myalgia and 
arthralgia that can last for months to years and may possibly result in symptoms 
synonymous with idiopathic inflammatory myopathies. Aspartate transaminase (AST) and 
alanine transaminase (ALT), monocyte chemoattractant protein (MCP)-1, tumour necrosis 
factor (TNF), interferon (IFN), Interleukin (IL), macrophage inflammatory protein (MIP), 
RANTES (CCL5) and reactive nitrogen intermediates (RNI).  
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Fig. 4. Time-course and histopathological data concerning CHIKV-infected patients. Patient 
#1, quadriceps biopsy was obtained during the CHIKV epidemic outbreak in the Reunion 
Island, presented a classical clinical picture of CHIKV infection. In addition, signs of 
rhabdomyolysis were reported. The muscle biopsy was performed on the quadriceps 
muscle 10 days post disease onset (illustrated by the red star). Patient #2 complained, in 
January 2006, of headaches, arthralgia and a rash; around three months later, she was 
admitted to hospital with a classical clinical picture of CHIKV infection, including myalgia. 
A biopsy was performed in the quadriceps muscle during this recurrent phase of the disease 
(red star). (A) and (B): Sections from the muscle biopsy of patient #1 H&E stained. (A) at x60 
magnification showing lack of cellular infiltrates. Atrophy and necrosis of muscle fibres 
could be seen, as well as central nuclei (arrow). (B): at x140 magnification showing 
vacuolization of muscle fibres. (C) and (D): Sections from the muscle of patient #2 showing 
an important mononuclear infiltration in H&E stained at x140 magnification (C) and fibrosis 
in Masson's trichrome stained sections at x80 magnification (D). © 2007 Ozden et al., 2007. 
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Fig. 5. Detection of CHIKV antigens from muscle biopsies of CHIKV infected patients. 
Detection of CHIKV antigens by immunofluorescence (IF) and immunoperoxydase (IP).  
(A–D): Detection of CHIKV in muscle biopsys from patient #1 located at the periphery of 
the myotubes, as multiple cells per microscopic field (A, D), or as single cell per field (B, C). 
Some immunoreactive cells (arrows) were detected at the periphery of muscle fibres with 
central nuclei (C, arrowhead). (E, F): Detection of CHIKV by IF in muscle biopsy sections 
from patient #1 (E) and #2 (F). Magnification: ×300(A,C,D,E,F); ×400(B). © 2007 Ozden et al. 
4.2 Cellular factors in alphavirus induced myopathies  
Histopathological analysis of patients with a range of myopathies has demonstrated 
inflammatory infiltrates in the muscle tissues, primarily macrophages (Hewer & Goebel, 
2008) and mononuclear cells. Infiltration of these cells is characteristic of idiopathic 
inflammatory myopathies. However, due to the lack of suitable animal models the 
mechanism by which inflammatory myopathies occur and the role that macrophages and 
mononuclear cells play in tissue pathology is poorly understood. 
In animal models of alphavirus induced disease, the inflammatory response seen in the 
joint, bone and skeletal muscle tissue following an acute infection is predominantly 
regulated by the innate immune system (Morrison et al., 2007; Morrison et al., 2006). The 
inflammatory infiltrates consist of macrophages, NK cells, CD4+ and CD8+ T cells. The key 
role of macrophages and monocytes in the pathogenesis of alphavirus disease was first 
identified using the mouse model of RRV infection (Lidbury et al., 2000). The selective 
depletion of macrophages by treatment of mice with macrophage-toxic agents such as silica 
or carrageenan, was found to almost entirely abrogate disease and the clearance of 
macrophages from damaged tissue correlated with recovery (Lidbury et al., 2000).  The high 
degree of macrophage and monocyte infiltration into infected tissues and joints has also 
been confirmed in the models of CHIKV infection (Gardner et al., 2010; Morrison et al., 2011). 
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The exact role that macrophages play in mediating disease is an area of ongoing research. It 
has been shown that infiltrating macrophages are a key mediator of muscle tissue 
destruction by mechanisms which involve the production of soluble factors such as 
macrophage inflammatory protein (MIP)-1, IFN-, interleukin (IL)-1, reactive nitogen 
intermediates (RNI), tumour necrosis factor (TNF)-, and monocyte chemoattractant protein 
(MCP)-1 (Lidbury et al., 2008). In the macaque model of CHIKV infection, an up-regulation 
of IFN-/, IFN-, MCPs, IL-6 and TNF- was detected, all synonymous with a strong, 
macrophage-induced inflammatory response (Labadie et al., 2010). IL-1, RNI and TNF- 
are factors known to trigger apoptosis (Bhaumik & Khar, 1998; Griffin & Hardwick, 1997; 
Roulston et al., 1999) while MCP-1 and MIP-1 are involved in amplifying the inflammatory 
response (Carr et al., 1994; Lidbury et al., 2008; Ren et al., 2010; Wolpe et al., 1988). 
Macrophages have also been implicated as a cellular reservoir for alphavirus persistence 
and therefore a contributing factor in the development of chronic disease symptoms. There 
have been numerous studies showing long-term persistence of RRV in macrophages in vitro 
(Linn et al., 1996; Linn et al., 1998; Way et al., 2002) however how this pertains to human 
infection is largely unknown. Recently, the study by Labadie et al., has shown macrophages 
act as a cellular reservoir for the persistence of CHIKV during the late stages of infection in 
macaques. This is the first in vivo study to show that CHIKV persistence in macrophages 
may be responsible for the long-lasting symptoms observed in humans. A study of viral 
persistence in macrophages during human infection has demonstrated evidence of CHIKV 
antigens in perivascular synovial macrophages in a CHIKV patient 18 months after the 
initial infection (Hoarau et al., 2010). Thus, it is reasonable to speculate that viral persistence 
in macrophages may trigger low levels of macrophage activation long term, which may 
contribute to chronic disease symptoms.  
To investigate the role of both T cells and the adaptive immune system in the development 
of RRV disease, studies were done on RAG-1 deficient mice, which lack functional T and B 
lymphocytes. Morrison et al., infected RAG-1 deficient with RRV and monitored for clinical 
signs of disease (Morrison et al., 2006). RAG-1 deficient mice developed disease signs similar 
to wild-type mice. Histological analysis revealed extensive myositis in the skeletal muscle 
with the inflammatory infiltrates identified as macrophages and NK cells, similar to 
observations in wild-type mice. Taken together, the results show that the adaptive immune 
response does not play a critical role in the development of RRV disease (Morrison et al., 
2006). Furthermore, the population of infiltrating CD4+ and CD8+ T cells found in the 
skeletal muscles of wild-type mice does not appear to play a role in the development of 
myositis as the absence of T and/or B cell functions does not affect disease development or 
outcome. Similar studies have been done using SINV infection in immunodeficient SCID or 
RAG-1 deficient mice. The studies found the clinical outcomes of SINV infection in 
immunodeficient neonatal mice to be comparable to that in immunocompetent neonatal 
mice (Burdeinick-Kerr et al., 2009; Levine & Griffin, 1993). Results of these studies suggest 
that the adaptive immune response does not play a role in the development of RRV-induced 
myositis and is not essential in the clinical outcome of alphaviral disease.  
4.3 Soluble factors in alphavirus induced myopathies 
There have been limited studies on the measurement of pro-inflammatory factors in serum 
and synovial aspirates taken from confirmed cases of RRV infection. The levels of 
complement factor C3a, MCP-1, TNF-, IFN- and RNI were all elevated in RRV patients 
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(Lidbury et al., 2008; Morrison et al., 2007). Furthermore, cells obtained from synovial fluid 
have been found to be mononuclear in nature being mainly monocytes and activated 
macrophages (Clarris et al., 1975; Fraser et al., 1981). In terms of RRV-induced myopathies, 
the limitations encountered in studying the pathogenesis in humans, particularly in 
investigating the role of soluble factors, have been achieved using a mouse model of RRV-
disease.  
Animal models have been used to determine the role of various cytokines and chemokines 
in the development of alphaviral-induced myopathies. Studies have shown that IFN-, TNF-
, IL-1, IL-6, macrophage inflammatory protein (MIP)-1, MCP-1, MCP-2, and MCP-3 are 
up-regulated in response to RRV infection (Lidbury et al., 2008; Rulli et al., 2009). The high 
levels of these factors in diseased tissues implicate their role in RRV-induced myositis 
(Lidbury et al., 2008; Rulli et al., 2009). Recently, a study by Rulli et al., showed that the 
MCPs inhibitor, bindarit, reduced RRV disease symptoms by decreasing myositis and 
muscle tissue destruction (Rulli et al., 2009). Bindarit down-regulated the production of 
chemokines MCP-1, -2 and -3, resulting in the reduction of macrophage recruitment into 
muscle tissues. These findings suggest a potential application of bindarit in the treatment of 
alphaviral-induced musculoskeletal disease such as myositis (Rulli et al., 2009).  
Several additional soluble factors have also been shown to play a role in the myositis that 
develops during the sub-acute phase of alphaviral infection. Studies using the RRV mouse 
model have shown that the complement component 3 (C3) contributes to the destructive 
phase of the inflammatory disease and promotes the development of severe myositis 
(Morrison et al., 2008). The main function of the complement system is to eliminate invading 
organisms. It is activated through a number of different pathways and is centered around 
the action of the protein C3. In the mouse model of RRV disease, C3 activation products 
were detected at the sites of RRV-induced inflammation and C3 was found to be critical for 
myositis and the tissue destruction phase of RRV-induced inflammatory myopathies 
(Morrison et al., 2007). Furthermore, mice deficient in functional receptor for C3 (CR3; 
CD11b deficient mice) showed significantly reduced disease symptoms and tissue 
destruction following RRV infection (Morrison et al., 2008), confirming the critical role of 
complement in the regulation of inflammatory processes at the site of alphaviral-induced 
myositis. These studies show complement to be a potential target for anti-viral therapies in 
treating alphavirus induced myositis.  
Similar to studies with RRV, analysis of serum samples from CHIKV-infected patients has 
also shown elevated levels of cytokines and chemokines. Of particular interest is the up-
regulation of IL-6, TNF-, IL-1, IFN-, interferon-inducible protein-10 (IP-10) and 
monokine induced by IFN- (MIG) (Hoarau et al., 2010; Ng et al., 2009b). There has been an 
association between high levels of viraemia in acute CHIKV-infected patients and a higher 
production of pro-inflammatory cytokines such as IL-6 and TNF- (Chow et al., 2011). 
Presentation of chronic disease symptoms has also been associated with elevated levels of 
IL-6 and granulocyte macrophage colony-stimulating factor (GM-CSF)(Chow et al., 2011). 
Whereas in patients who have fully recovered from disease, high levels of eotaxin and 
hepatocyte growth factor have been detected (Chow et al., 2011).  
Analysis of pro-inflammatory mediators in an adult C57BL/6 mouse model of CHIKV 
disease revealed an up-regulation in the expression of TNF-┙, MCP-1, IFN-┛, IL-6 and IFN-
┙/┚ in the sera of infected mice (Gardner et al., 2010). These results were consistent with 
findings using the macaque model of CHIKV disease where IFNs were shown to play an 
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important role in CHIKV pathogenesis, with IFN-/ and IFN-, along with IL-6 and MCP-
1, up-regulated at 2-10 days p.i. (Labadie et al., 2010).  
In patients with idiopathic inflammatory myopathies, the levels of several cytokines 
including MCP-1 and TNF- are elevated (Bartoli et al., 2001). A large number of studies 
have suggested a role for IL-1, IFN- and TNF- as mediators of inflammatory myopathies 
(Lundberg, 2000; Lundberg & Dastmalchi, 2002; Salomonsson & Lundberg, 2006). TNF has 
been extensively implicated in idiopathic inflammatory myopathies and is a potential 
therapeutic target. Enbrel® is an anti-TNF- drug used to treat rheumatoid arthritis; has 
also given promising results in the treatment of myositis (Sprott et al., 2004). Although TNF 
is similarly increased in alphavirus disease and myositis, Enbrel® treatment has been shown 
to both increase virus titre and alphavirus myositis (Zaid et al., 2011). Therefore the use of 
anti-TNF therapy is not recommended in people presenting with myositis in which 
alphaviruses have not been ruled out as a potential causative agent.  
4.4 Muscle enzymes in alphavirus induced myopathies 
In addition to the roles of cytokines and chemokines in mediating alphavirus-induced 
myositis, muscle enzymes are also implicated in disease.  Studies from the Reunion 
outbreak have found myalgia to be a major symptom of CHIKV infection (Paquet et al., 
2006). Elevated levels of creatine phosphokinase (CPK), a muscle enzyme marker for 
idiopathic inflammatory myopathies, and rhabdomyolysis have been reported in cases of 
CHIKV-infection (Lundberg, 2001). Ozden et al., analysed muscle biopsies of CHIKV-
infected patients and in one case, a CHIKV-infected patient in the sub-acute phase presented 
with rhabdomyolysis with elevated CPK (41600 IU/mL) in addition to symptoms of 
myalgia and elevated myoglobin. Demonstrating a similarity between idiopathic 
inflammatory myopathies and alphavirus-induced myositis (Ozden et al., 2007). 
5. Alphaviruses and idiopathic inflammatory myopathies (IIM) 
The term idiopathic inflammatory myopathies (IIM) is used to describe myopathy arising 
from an unknown cause which involves inflammation of the muscles. The term 
encompasses a group of three related muscles disorders (Polymyositis, Dermatomyositis 
and Body Inculsion Myositis), which can be distinguished by clinical, histopathological, and 
immunological features (Lundberg & Dastmalchi, 2002). 
Identification of possible triggers for IIM has been the topic of numerous studies with a 
focus on investigating the potential role of infectious agents in the aetiology of IIM. It has 
long been suspected that infectious agents may have a direct role in IIM with bacteria and 
viruses (notably retroviruses and entroviruses) being frequently implicated (Ytterberg, 
1996). As muscle inflammation is one of the primary symptoms of the acute and sub-acute 
stages of viral infection, it is thought that the onset of an idiopathic inflammatory myopathy 
could be triggered by a chronic underlying viral infection.   
The ability of alphaviruses to cause persistent and chronic infections has been recently 
studied with the demonstration of  the presence of viral antigens in the muscle and synovial 
tissue of infected patients (Hoarau et al., 2010; Ozden et al., 2007). Invading pathogens can 
cause muscle tissue damage in both direct (by means of infection), and indirect (involving 
immune mediated damage) mechanisms. The question that remains is whether, in cases of 
IIM where virus antigen is no-longer detected, is it possible that virus persistence at an 
earlier stage triggers an immune response which continues for prolonged periods? There 
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have been numerous studies on the potential long-term disease sequelae due to alphavirus 
infection, suggesting that long-term chronic illness, lasting for years, may occur (Fraser, 
1986; Harley et al., 2002; Laine et al., 2000; Mylonas et al., 2002; Niklasson & Espmark, 1986; 
Niklasson et al., 1988). However these studies have been unable to conclusively demonstrate 
alphaviruses as the cause of the symptoms presented. A lack of differential diagnosis, 
combined with potential underdiagnosis of other conditions that may exist concurrently in 
patients, and the lack of experimental long-term disease models, has led to the uncertainty 
regarding the level of long-term alphavirus disease.  
Current medical practice requires cultures and/or other direct diagnostic tests to confirm 
the causative agents of infectious myositis. In the absence of such diagnosis the clinical 
manifestations observed in a patient are termed idiopathic. It is suspected that the time 
between the primary infection and the related immunological clinical representation is so 
great that clinicians are ill-equipped to make a proper diagnosis using current medical 
practices. Therefore what is in reality an infectious myositis becomes inaccurately diagnosed 
as an idiopathic inflammatory myopathy. 
6. Conclusion  
The increasing frequency and severity of alphavirus epidemics highlights the importance of 
these viruses in the incidence of inflammatory myopathies. At present, knowledge is lacking 
in the clinical aspects of human myositis following alphavirus infections with speculation 
that virus persistence in the muscle and macrophages may explain the recurrent and chronic 
symptoms of myalgia. In addition the correlation between a previous exposure to an 
alphavirus infection and the development of idiopathic inflammatory myopathies is ill-
defined, with current diagnostic tests unable to isolate alphaviruses or detect alphavirus 
antigen in the presenting patient. It is evident that further research is needed to fully 
understand the aetiology and pathobiology of alphavirus-induced inflammatory 
myopathies. The establishment of animal models of chronic alphavirus disease would be of 
immense benefit in bridging the gap in our understanding of the role of viral infections in 
chronic myositis. Such a model will also be of value in dissecting disease mechanisms as 
well as investigate new treatment modalities.   
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